Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android

Chapter 7: Carcinoma of Unknown Primary

David R. Spigel; F. Anthony Greco

INTRODUCTION

Epidemiology

|Download (.pdf)|Print
Epidemiology
Incidence: Unknown✫ (Estimated at 30,000–45,000 patients/year) Stage at Presentation
Median age: Varies by histology (usually sixth decade) Local/regional: <10%
Male to female ratio: M ≅ F ≥2 sites: >90%

✫Due to patient heterogeneity and tumor registry misclassification

 

Cancer Facts and Figures 2013, the America Cancer Society

Greco FA, Hainsworth JD. In: DeVita VT, Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, 8th ed. Lippincott; 2008:2363–2388

Hainsworth JD et al. J Clin Oncol 1991;9:1931–1938

Hainsworth JD, Greco FA. N Engl J Med 1993;329:257–263

Pathology

|Download (.pdf)|Print
Pathology
Adenocarcinoma (well differentiated or moderately differentiated) 60%
Poorly differentiated carcinoma/(± features of adenocarcinoma) 29%
Poorly differentiated malignant neoplasm 5%
Squamous carcinoma 5%
Neuroendocrine carcinoma 1%

Greco FA, Hainsworth JD. In: DeVita VT, Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, 8th ed. Lippincott; 2008:2363–2388

Hainsworth JD, Greco FA. N Engl J Med 1993;329: 257–263

Work-up

Clinical evaluation

  • H&P, including pelvic, breast, and rectal exams

  • CBC

  • Comprehensive metabolic profile

  • Urinalysis

  • Occult blood in feces

  • Lactate dehydrogenase (LDH)

  • Serum human chorionic gonadotropin (HCG)

  • Alpha-fetoprotein (AFP)

  • Carcinoembryonic antigen (CEA)

  • CA 19-9, CA 27–29 (or CA 15-3), CA 125

  • Chest/abdominal/pelvic CT

Where appropriate:

  • Positron emission tomography (PET)

  • Prostate specific antigen (PSA)

  • Mammography, bronchoscopy, and panendoscopy (particularly for squamous carcinomas)

Pathologic studies

  • Core needle or excisional biopsy preferred over fine-needle aspiration (FNA)/cytology (consider rebiopsy if insufficient material from initial biospy)

  • Immunohistochemistry (IHC) analyses for:

    • PSA in men

    • Estrogen receptor (ER) in women

    • Progesterone receptor (PR) in women

    • HER2/neu overexpression in women

    • CD 117

    • Consider gene signature profiling of tissue of origin

Where appropriate:

  • Electron microscopy

  • Cytogenetic analysis

  • Molecular profiling

Focused Work-up

|Download (.pdf)|Print
Focused Work-up
Presentation Men Women
Head and neck or supraclavicular adenopathy

  • ENT exam

  • Chest/abdominal CT

  • PSA, testicular ultrasound

  • ENT exam

  • Chest/abdominal CT

  • Mammography, ER/PR

  • Pathologic evaluation
Axillary adenopathy

  • Chest/abdominal CT

  • PSA

  • Chest/abdominal CT

  • Mammography, ER/PR

  • (Consider ultrasound or MRI)
Mediastinal involvement

  • Chest/abdominal CT

  • HCG/AFP

  • PSA

  • Chest/abdominal CT

  • HCG/AFP

  • Mammography, ER/PR
Chest (effusion and/or nodules) involvement

  • Chest/abdominal CT

  • PSA

  • Chest/abdominal/pelvic CT

  • Mammography, ER/PR

  • CA 125
Peritoneal involvement

  • Chest/abdominal/pelvic CT

  • PSA

  • Chest/abdominal/pelvic CT

  • Mammography, ER/PR

  • CA 125
Retroperitoneal mass

  • Chest/abdominal/pelvic CT

  • PSA

  • HCG/AFP

  • Testicular ultrasound

  • Chest/abdominal/pelvic CT

  • Mammography, ER/PR

  • CA 125
Inguinal adenopathy

  • Abdominal/pelvic CT

  • PSA

  • Abdominal/pelvic CT

  • Mammography, ER/PR

  • CA 125
Hepatic involvement

  • Chest/abdominal/pelvic CT

  • Colonoscopy

  • AFP

  • PSA

  • Chest/abdominal/pelvic CT

  • Colonoscopy

  • AFP

  • Mammography, ER/PR
Skeletal involvement

  • Bone scan

  • PSA

  • Bone scan

  • Mammography, ER/PR
Brain involvement

  • Chest/abdominal CT

  • Chest/abdominal CT

  • Mammography, ER/PR

Greco FA, Hainsworth JD. In: DeVita VT, Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, 8th ed. Lippincott; 2008:2363–2388

Survival

  • 1-Year survival: 35–40%

  • 2-Year survival: 15–20%

  • 3-Year survival: 10–15%

  • 5-Year survival: 10%

  • 8-Year survival: < 10%

Survival varies by histology and clinical subsets

...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.

This site uses cookies to provide, maintain and improve your experience. MH Privacy Center Close